abbott laboratories inc. Resources | BNET
On CNET: Full review of iPhone 3G: Hot or not?

BNET Industries

Abbott Laboratories Inc. (ABT) is in the Pharma Industry

Revenue
Dec 31 2007
$25.9B
Profit
Dec 31 2007
$3.6B
Market Cap
Jul 17 2008
$1.7M

Latest News and Analysis

Additional Resources

  • BellwetherReport.com Analyst Report on ABT, FDG, NUE and OCTL

    BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

    Articles 2008-07-08

  • Antares Pharma Appoints Paul Wotton, Ph.D. as President and Chief Operating Officer

    EWING, N.J. -- Antares Pharma, Inc. (AMEX:AIS) announced that Paul K. Wotton, Ph.D., has joined Antares Pharma as President and Chief Operating Officer. Dr. Wotton has over 20 years experience in the pharmaceutical industry with both large and specialty pharma companies. Previously, Dr. Wotton served as CEO of...

    Articles 2008-07-07

  • Seven Summits Research Releases Comments on AA, ABT, STZ, SGR and PBG

    CHICAGO, July 7 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to: http://www.iotogo.com/StocksToWatch) provides investors with essential information on stocks that may be poised for a significant move. By featuring hedged...

    Articles 2008-07-07

  • New Drug-Coated Stent Approved

    The Xience drug-coated stent, used to prop open a blocked or narrowed artery in people with coronary artery disease, has been approved by the U.S. Food and Drug Administration, maker Abbott Laboratories said. A stent is a metal-mesh tube that's inserted into the artery. The drug, everolimus, helps prevent the...

    Articles 2008-07-03

  • Learn about the World Molecular Diagnostics Market

    Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Molecular Diagnostics Market http://www.reportlinker.com/p090566/World-Molecular-Diagnostics-Market.html This report analyzes the worldwide markets for Molecular Diagnostics in Millions of US$. The specific product segments analyzed are Infectious Disease...

    Articles 2008-06-24

  • page 1 of 168
  • Incorporated: 1900
  • CEO: Mr. Miles D. White

Abbott Laboratories is principally engaged in the discovery, development, manufacture and sale of a variety of health care products through four business segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Co.'s primary products are prescription pharmaceuticals, nutritional products, vascular products and diagnostic testing products. In addition, Co. has a 50.0%-owned joint-venture, TAP Pharmaceutical Products Inc. with Takeda Pharmaceutical Company Ltd. of Japan, through which Co. develops, markets and sells pharmaceutical products such as Lupron®, Lupron Depot® and Prevacid® (lansoprazole), within the U.S., Puerto Rico and Canada.

Key Competitors

Abbott Laboratories Inc. Company Info

Board of Directors

Mr. Miles D. White

Chairman

Mr. Roy S. Roberts

Mr. Samuel C. Scott III

Mr. William D. Smithburg

Mr. Glenn F. Tilton

Ms. Roxanne S. Austin

Mr. William M. Daley

Mr. W. James Farrell

Mr. H. Laurance Fuller

Mr. William A. Osborn

The Rt. Hon. Lord David Owen

Mr. Boone Powell Jr.

Dr. W. Ann Reynolds Ph.D.

Contact Information

100 Abbott Park Road

Abbott Park, IL

http://www.abbott.com

847 937-6100

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412